Shanghai NewMed Medical Co., Ltd.
9
4
5
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 9 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
Mi-thos® Transcatheter Mitral Valve Replacement Study
Role: lead
Phimume® Percutaneous Left Ventricular Assist System Study
Role: lead
Phitys I™ Percutaneous Left Ventricular Assist System Study
Role: lead
Prizvalve® Transcatheter Atrioventricular Valve Replacement Study
Role: lead
Valveclip® Transcatheter Mitral Valve Repair Study
Role: lead
Prizvalve Pro™ Transcatheter Aortic Valve Replacement Study
Role: lead
Prizvalve® Transcatheter Valve-in-Valve Implantation Exploratory Study
Role: lead
PrizValve® Transcatheter Aortic Valve Replacement Study
Role: lead
Mi-thos® Transcatheter Mitral Valve Replacement(First-in-Man Study)
Role: lead
All 9 trials loaded